Biomerica (BMRA) Peer Comparison
$2.26
$0.04
(1.80%)
As on 04-Sep-2026 11:33EDT
Market cap
$7 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Edit
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
7 | 4,924 | 2,543 | 722 | 655 |
Revenue ($ Mln) |
4 | 1,352 | 870 | 250 | 320 |
Net Profit ($ Mln) |
-4.17 | 96.29 | -7.90 | 4.80 | -36.74 |
Net Margin (%) |
-96.49 | 7.12 | -0.91 | 1.92 | -11.48 |
RoE (%) |
-98.54 | 11.01 | -0.38 | 2.56 | -20.77 |
Price to Earnings |
-- | 52.28 | -- | 151.87 | -- |
Price-To-Book |
1.96 | 5.89 | 1.22 | 3.82 | 3.82 |
Income Statement ($ Mln)
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
5.31 | 1,352.01 | 894.66 | 249.73 | 292.50 |
|
Cost of Revenue
|
4.81 | 576.17 | 473.29 | 84.94 | 134.79 |
|
Gross Profit
|
0.50 | 778.55 | 421.38 | 150.87 | 157.71 |
|
Operating Expenses
|
5.64 | 530.10 | 411.96 | 142.31 | 197.66 |
|
Operating Profit (EBIT)
|
-5.14 | 245.74 | 9.42 | 22.48 | -39.95 |
|
Other Income
|
-- | 0.00 | -- | 0.00 | -- |
|
Profit before Tax
|
-4.97 | 130.44 | -1,133.11 | 9.36 | -34.03 |
|
Provision for Tax
|
0.00 | 34.15 | -41.07 | 4.56 | -0.04 |
|
Profit after Tax (Net Income)
|
-4.97 | 96.29 | -1,092.04 | 4.80 | -33.99 |
|
Minority Interest
|
-- | 0.00 | -- | 0.00 | -- |
|
Consolidated Profit
|
-- | 83.42 | -- | 0.00 | -- |
Liabilities ($ Mln)
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
4.11 | 837.10 | 2,071.25 | 188.76 | 182.97 |
|
Minority Interest
|
-- | 0.00 | -- | 0.00 | -- |
|
Non-Current Liabilities
|
0.10 | 1,265.06 | 1,198.57 | 173.14 | 20.98 |
|
Current Liabilities
|
1.74 | 263.24 | 174.01 | 49.65 | 76.20 |
|
Total Liabilities
|
5.95 | 2,450.95 | 3,443.84 | 433.35 | 280.14 |
Assets ($ Mln)
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1.07 | 1,554.57 | 2,866.90 | 316.38 | 111.82 |
|
Current Assets
|
4.88 | 810.83 | 576.94 | 102.85 | 168.32 |
|
Total Assets
|
5.95 | 2,450.95 | 3,443.84 | 433.35 | 280.14 |
|
Total Debt*
|
0.46 | 1,174.16 | 912.61 | 101.36 | 10.15 |
|
Net Current Assets
|
3.14 | 547.60 | 402.93 | 0.00 | 92.13 |
Cashflow ($ Mln)
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-3.84 | 181.73 | 58.24 | 46.81 | -10.13 |
|
Cash Flow from Investing Activities
|
-0.04 | -161.90 | -99.20 | -4.50 | -10.18 |
|
Cash from Financing Activities
|
2.11 | 108.82 | -1.60 | -44.51 | -0.26 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-83.31 | 8.79 | -31.05 | -0.55 | -16.85 |
|
ROE (%)
|
-92.99 | 11.01 | -41.88 | 2.56 | -17.50 |
|
ROA (%)
|
-65.44 | 3.43 | -27.33 | 0.87 | -11.37 |
|
EBIT Margin (%)
|
-- | 11.18 | -- | 7.05 | -- |
|
Net Margin (%)
|
-93.64 | 7.12 | -122.06 | 1.92 | -11.62 |
|
Cash Profit Margin (%)
|
-- | 0.00 | -- | 0.00 | -- |
Growth Ratios
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.02 | 0.44 | -0.03 | 3.04 | -0.04 |
|
EBIT Growth (%)
|
-- | -42.21 | -- | -10.33 | -- |
|
Net Profit Growth (%)
|
16.81 | -41.05 | -11,491.59 | 874.19 | 81.56 |
|
EPS Growth (%)
|
-- | -37.43 | -- | 710.00 | -- |
|
Book Value Growth (%)
|
-- | 0.38 | -- | 5.55 | -- |
Valuation Ratios
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 18.75 | -- | -326.35 | -- |
|
Price / Book Value
|
-- | 3.83 | -- | 4.03 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.42 | 11.41 | -0.84 | 18.85 | -26.32 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.11 | 1.40 | 0.44 | 0.00 | 0.06 |
|
Short term debt to equity ratio
|
0.09 | 0.01 | 0.01 | 0.04 | 0.01 |
|
Current Ratio
|
2.80 | 3.08 | 3.32 | 2.07 | 2.21 |
|
Quick Ratio
|
1.95 | 1.91 | 2.22 | 1.52 | 1.40 |
|
Interest Coverage
|
-- | 5.26 | -14.85 | 1.86 | -20.97 |
Operating Efficiency Ratios
| Biomerica (BMRA) | Haemonetics (HAE) | Neogen (NEOG) | Mesa Laboratories (MLAB) | AngioDynamics (ANGO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
13.76 | 15.98 | 17.14 | 13.78 | 14.75 |
|
Asset Turnover
|
0.70 | 0.48 | 0.22 | 0.45 | 0.98 |
|
Receivable days
|
57.70 | 54.92 | 66.63 | 61.40 | 58.16 |
|
Inventory Days
|
146.69 | 214.01 | 146.68 | 117.63 | 166.14 |
|
Payable days
|
22.12 | 44.02 | 62.77 | 23.89 | 96.25 |
|
Cash Conversion Cycle
|
182.27 | 224.91 | 150.54 | 155.15 | 128.04 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
